ArticleEULAR rheumatology open2026
Individual patient disease activity expression profiles modify the relation between disease activity and structural damage progression in RA.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Disease activity in rheumatoid arthritis (RA) is commonly assessed using composite indices such as the Disease Activity Score in 28 Joints (DAS28). However, individual disease activity markers can be more or less pronounced in patient subgroups, and markers beyond disease activity indices may contribute to relevant disease activity patterns. This study aimed to identify patient subgroups with 'disease activity expression profiles' and evaluate their relevance. Methods: Routine-care data at University Medical Center Utrecht were extracted. Seventeen parameters associated with disease activity were included in a clustering analysis, with the optimal number of clusters determined using fit statistics and clinical interpretation. Using random effects modelling, the association between DAS28 and radiographic progression was assessed, including whether this relation was modified by expression profile. Results: Among 1167 patients with RA, three disease activity expression profiles were identified: (i) Systemic inflammatory (n = 330), characterised by high swollen joint counts and elevated inflammatory markers; (ii) Symptom dominant (n = 191), marked by high patient-reported activity and tender-swollen joint discrepancy; and (iii) Low-typical (n = 646), with low-to-moderate disease activity and less divergent marker expression. Higher DAS28 was associated with radiographic progression (odds ratio = 1.40 [1.03-1.92], Conclusions: Derived disease activity expression profiles influence the predictive value of DAS28. Taking identified expression profiles into account may improve disease activity interpretation and support tailored monitoring and management in RA.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.